Skip to main content
OpenTrials
Completed

NCT Number: NCT05210335

RISK ANALYSIS AND MANAGEMENT FOR MEDICATION OPTIMIZATION IN THE PREOPERATIVE AND POSTOPERATIVE PERIOD OF CARDIAC SURGICAL PATIENTS

Optimal perioperative and long-term success in cardiac-surgery require precise management of drug treatment. This study was aimed to determine prevalence, types and associated factors of drug related problems (DRPs) at both preoperative and postoperative stages in patients at cardiac-surgery by using risk analysis method.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Drug Related Problems Cardiac Surgery Clinical Pharmacy Risk Assesment

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hacettepe University Faculty of Pharmacy Department of Clinical Pharmacy

Ankara, Altındağ, 06100, Turkey (Türkiye)

About this study

Cardiac surgery becomes a life-saving option in patients once medical treatments become inadequate. In order to achieve optimal perioperative and long- term success in cardiac surgery, drug treatment should be managed precisely. Patients with cardiovascular diseases are at risk for developing drug related problems (DRPs) due to polypharmacy and having received high-alert medications, such as antiarrhythmics or antithrombotic agents. In addition, type of operation (multiple artery bypass or combined valve procedures), existence of chronic atherosclerotic diseases (such as diabetes mellitus, hypertension), length of stay (LOS) at hospital, frailty, changes in medications for unstable cardiac conditions, incomplete or inadequate history for medication at hospital admission, transition between wards by different healthcare teams and transfer of discrepancies throughout entire perioperative period contributes to increased risk of DRPs in patients at cardiac surgery. It has been shown that over one third of patients suffer from DRPs during hospitalization. Clinical pharmacists are in a position to identify and prevent DRPs, therefore can help to provide optimal pharmaceutical treatment by performing medication reconciliation, improving patient compliance, monitoring of laboratory values and conducting patient education for surgical patients.However, there is limited information about prevalence and risk factors of DRPs in patients at cardiac surgery, in particular with perioperative stages. Majority of studies regarding DRPs have been conducted in specific populations such as elderly, pediatrics or in general medicine. Therefore this study was aimed to determine prevalence, types and associated factors of drug related problems (DRPs) at both preoperative and postoperative stages in patients at cardiac-surgery by using risk analysis method.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients are aged 18 years or older
  • admitted to the hospital for a planned elective cardiac surgery during the study period were considered eligible.

Exclusion criteria

  • Patients who refused to participate,
  • transferred from different wards
  • have urgent surgery planned were excluded

Treatment and study plan

Clinical pharmacist's recommendation to physicians about drug related problems

Other

Clinical pharmacist's recommendation to physicians about drug related problems

Primary outcomes

  1. Obtaining drug related problems preoperative and postoperative periods

    Time frame: 6 months (1 November 2019-30 March 2020)

    Obtaining valid drug related problems and their characteristic is the primary outcome as a part of the risk analysis.

  2. Building risk analysis model

    Time frame: 3 months (30 March 2020-30 June 2020)

    In line with the valid drug related problems expert panel build the model

  3. Obtaining clinical pharmacist affect

    Time frame: 6 months (1 August 2020- 30 January 2021)

    Obtaining clinical pharmacist affect as a part of the risk analysis model

Secondary outcomes

  1. Obtaining clinical pharmacist intervention on other factors

    Time frame: 6 months (1 August 2020- 30 January 2021)

    the affect of this model on quality of life, nutritional status, fraility status, hospital mortality rate, length of hospital stay, lenght of intensive care unit stay.

Sponsors and collaborators

Lead sponsor

Hacettepe University

Other

Registry information

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Jan 27, 2022
Registry last updated
Jan 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.